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ABSTRACT Transmissible spongiform encephalopathies are neurodegenerative diseases characterized by the accumulation
of an abnormal isoform of the prion protein PrPSc. Its fragment 106-126 has been reported to maintain most of the pathological
features of PrPSc, and a role in neurodegeneration has been proposed based on the modulation of membrane properties and
channel formation. The ability of PrPSc to modulate membranes and/or form channels in membranes has not been clearly
demonstrated; however, if these processes are important, peptide-membrane interactions would be a key feature in the toxicity
of PrPSc. In this work, the interaction of PrP(106-126) with model membranes comprising typical lipid identities, as well as more
specialized lipids such as phosphatidylserine and GM1 ganglioside, was examined using surface plasmon resonance and
ﬂuorescence methodologies. This comprehensive study examines different parameters relevant to characterization of peptide-
membrane interactions, including membrane charge, viscosity, lipid composition, pH, and ionic strength. We report that
PrP(106-126) has a low afﬁnity for lipid membranes under physiological conditions without evidence of membrane disturbances.
Membrane insertion and leakage occur only under conditions in which strong electrostatic interactions operate. These results
support the hypothesis that the physiological prion protein PrPC mediates PrP(106-126) toxic effects in neuronal cells.
INTRODUCTION
Prion diseases, also known as transmissible spongiform en-
cephalopathies (TSEs), are human and animal diseases
characterized by progressive neuronal loss, which is often
accompanied by a spongiform brain alteration and the de-
position of amyloid fibrils. These diseases appear in sporadic,
familial, and infectiously acquired forms, and are invariably
fatal without evoking any inflammatory or immune response
in the host (1). Interest in prion diseases has grown as a result
of the emergence of bovine spongiform encephalopathy and
the possible infection of human beings (2).
The pathology of prion diseases is initiated by posttrans-
lational modification of a native glycoprotein, termed prion
protein (PrP), that is abundantly expressed in the central
nervous systemofmammalian species.Apathological scrapie
form, PrPSc, interacts with the physiological form, PrPC,
which is converted into subsequent scrapie-form molecules
(PrPSc1PrPC/ 2 PrPSc). Themechanism of this conversion
is not well understood, but it likely takes place at the
cell surface or, more specifically, in raft domains, where the
PrPC is preferentially located because of its glycosylphos-
phatidylinositol (GPI) anchor (see Naslavsky et al. (3) and
Pinheiro (4) and references therein).
The two PrP isoforms possess different physicochemical
properties: PrPC has an a-helical structure that is susceptible
to enzymatic digestion, whereas PrPSc has a large b-structure
component but is resistant to proteolysis. The PrPSc forms
highly insoluble, b-structure aggregates within the brain and
is believed to be responsible for the neurological damage that
occurs in prion diseases (5). However, PrPSc aggregates are
not the only cause of pathology. It has been observed that
PrPSc accumulates in intracellular compartments, and other
forms of PrP (i.e., transmembrane forms (6) and a cytosolic
form (7)) have also been identified. This suggests that the
endosomal pathway may also be involved in disease propa-
gation, where all these forms can be involved and take part in
the propagation of the disease (see Kourie (6) and Campana
et al. (8) and references therein). As a consequence of the
complex pathology, the time course of PrPSc accumulation is
not coincident with the time course of neurodegeneration (6).
Among all of the synthetic prion-derived peptides that
have been studied, the fragment spanning the human PrP
region 106-126 (KTNMKHMAGAAAAGAVVGGLG) has
been identified as the most highly amyloidogenic region with
neurotoxic activity. It also has the capacity to readily form
fibrils (9), being partially resistant to proteolysis (10). Based
on these observations, it was postulated that PrP(106-126)
may be a major contributor to the physicochemical and
pathogenic properties of PrPSc (11) with a role in amyloid
formation and in the nerve cell degeneration that occurs in
prion-related encephalopathies, and therefore PrP(106-126)
was proposed as a model peptide of infectious forms of PrP
(10). This evidence is supported by observations that the
PrP(106-126) sequence is present in all abnormal PrP iso-
forms accumulated in patient brains (11), and suggests that
this region may possess the ability to trigger or enable a
fundamental pathogenic mechanism common to different
forms of prion disease (12).
The amphipathic primary structure of PrP(106-126) is
characterized by two domains: the N-terminal positive and
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hydrophilic domain (KTNMKHM) and the C-terminal hy-
drophobic (AGAAAAGAVVGGLG) domain, which sug-
gests a propensity to interact with cell membranes (13).
Previous studies of the interaction of PrP (106-126) with
model membranes have shown that pH and ionic strength are
critical for secondary structure and membrane interactions,
and an increased affinity for membranes at acidic pH with a
concomitant increase in b-sheet content has been reported.
These studies thus support the hypothesis that the endosomal
pathway is involved in PrPSc formation/propagation through
neuronal cells, and the PrP(106-126) region may have an
effect on prion disease toxicity (14,15).
Despite the plausibility of implicating PrP(106-126) in
prion disease toxicity, Fioriti et al. (12) found no evidence for
PrP(106-126) infection or ability for conversion of PrPC to
PrPSc or to any other toxic PrP species. It has therefore been
suggested that PrP(106-126) is not toxic by itself, but be-
comes neurotoxic in the presence of the PrPC form (12,16–
18), and that this toxicity is the possible result of an alteration
of physiological functions of PrPC instead of an effect in-
duced by the PrP(106-126) fragment per se (12). Membrane
pore formation induced by PrP(106-126) may also be an
explanation for PrP toxicity, as shown by electrophysiolog-
ical studies (19,20). However, this hypothesis is also con-
troversial because pore formation (21) and neurotoxicity (22)
were not confirmed by other groups.
Because of controversies surrounding PrP(106-126) tox-
icity, and a lack of clarity regarding a physiological role for
PrP(106-126), we chose to investigate the interaction of
PrP(106-126) with membranes. Because biological mem-
branes are exceedingly complex, it is often necessary to re-
duce the number of membrane components to enable
meaningful studies. However, since peptide-membrane in-
teractions are often governed by the physicochemical prop-
erties of the lipid bilayer, the use of simplified model
membranes, such as vesicles (e.g., large unilamellar vesicles
(LUVs)), instead of neuronal cells or cellular extracts is
preferred. Our experiments were carried out by means of
surface plasmon resonance (SPR) with supported lipid bilay-
ers, and by fluorescence spectroscopy methodologies with
LUVs. Specifically, we investigated PrP(106-126)’s affinity
for membranes, including the kinetics of PrP(106-126)
membrane interactions, and the effects of PrP(106-126) on
membrane stability, and the possibility of PrP(106-126) pore
formation. Different conditions, including membrane charge,
viscosity, lipid composition, pH, and ionic strength, were
studied. The interaction between PrP(106-126) and mem-
branes appears to be significant only at low ionic strength
and high anionic-phospholipid content, which are non-
physiological conditions, and no evidence was found to
support pore formation in the membranes. However, our data
support models of PrP(106-126) toxicity in which a loss/
modification of biological PrPC function occurs within neu-
ronal cells, as opposed to PrP(106-126) peptide being toxic
by itself.
MATERIALS AND METHODS
Materials
PrP(106-126) with purity higher than 95% was obtained from Genescript
Corp. (Piscataway, NJ); N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic
acid (HEPES), sodium chloride, L-tryptophan, acrylamide, ethanol, and
chloroform were obtained from Merck (Darmstadt, Germany). The lipids
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-
2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) (POPG), 1-palmitoyl-
2-oleoyl-sn-glycero-3-(phospho-rac-(1-serine)) (POPS), 1,2-dipalmitoyl-
sn-glycero-3-phosphocholine (DPPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-
(phospho-L-serine) (POPS), 1,2dipalmitoyl-sn-glycero-3-phosphoethanola-
mine-N(7-nitro-2-1,3-benzoxadiazol-4-yl) (N-NBD-PE), and monoganglio-
side GM1 were obtained from Avanti Polar-Lipids (Alabaster, AL). Congo
red (CR), thioflavin T (ThT), (3-[3-cholamidopropyl)-dimethylammonio]-1-
propanesulfonate (CHAPS), and cholesterol (chol) were obtained from
Sigma-Aldrich (St. Louis, MO); and tris-(2-cyanoethyl)phosphine (TCEP),
1-anilinonaphthalene-8-sulfonic acid (1,8-ANS), and 4-(2-[6-(dioctylamino)-
2-naphthalenyl]ethenyl)-1-(3-sulfopropyl)-pyridinium (di-8-ANEPPS) were
obtained from Molecular Probes (Eugene, OR).
Working conditions and apparatus
PrP(106-126) was dissolved in sterile water to a concentration of 2mg/mL (1.05
mM) before dilution with buffer to working conditions as described below.
Experiments were conducted with final peptide concentrations in the 0–50 mM
range, which is a typical concentration range for the study of cytotoxic effects
and peptide aggregation (12,23–25). Throughout this study, the effect of pH
was evaluated by comparing cytoplasmic physiological conditions (10 mM
HEPES, pH 7.4, 150 mM NaCl) with a pH 5 endosomal mimetic (20 mM
sodium acetate, pH 5, 150 mMNaCl). The effect of low ionic strength was also
evaluated at pH 5 (20 mM sodium acetate, 10 mM NaCl). Experiments were
performed at room temperature (25C), under conditions where 1-Palmitoyl-
2-Oleoyl-sn-phosphatydilcholine was in the fluid phase. A Jasco V-560 UV-vis
spectrophotometer was used for all UV-vis measurements. Steady-state fluo-
rescence measurements were carried out in a Spex FluoroLog-3 (Horiba Jobin
Yvon, Edison, NJ) with double excitation and emission monochromators and a
450W xenon lamp. SPR measurements were performed in a Biacore T100
(Biacore-GE Healthcare, Uppsala, Sweden) with series S L1 sensor chips.
Circular dichroism (CD) measurements were performed on a Jasco J-810
spectropolarimeter equipped with a temperature control unit.
Intermolecular b-structures determined by
thioﬂavin T and CR
The presence of b-structures was analyzed by fluorescence emission of ThT
(26) and CR absorbance (27,28). Titration of 15 mMThT with PrP(106-126)
was followed by fluorescence spectra with lexcitation ¼ 450 nm. CR ab-
sorption was followed by titration of 5 mM CR with a stock solution of
PrP(106-126) to give final peptide concentrations in the range of 0–50 mM.
Peptide aggregation followed by
ANS ﬂuorescence
The effect of peptide concentration on PrP(106-126) aggregation was fol-
lowed by means of ANS fluorescence emission (29–31) with excitation at
369 nm; 12.8 mM ANS (A369; 0.1) was used through the experiments and
titrated with a stock solution of PrP(106-126) to yield a final peptide con-
centration in the range of 0–50 mM.
Lipid vesicles preparation for
peptide-membrane studies
LUVs are good model membranes because they have a large surface cur-
vature that forms a consistent and stable membrane mimetic for equilibrium
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studies (17,18,32). With these model membranes, different properties can be
modulated (e.g., lipid charge, membrane viscosity, the presence of a sterol,
the effect of pH, and ionic strength). The use of different lipid mixtures also
allows the influence of selected membrane features or properties on peptide
association or insertion to be explored. The LUVs used in this study were
prepared from lipid films using a combination of freeze-thaw fracturing and
sizing by extrusion as previously described (33). Briefly, lipid solutions in
chloroform were dried under a stream of N2 and residual organic solvent was
removed in vacuo (16 h). The lipid film was hydrated with the desired buffer
and subjected to eight freeze-thaw cycles to produce multilamellar vesicles
(MLVs). The MLVs were extruded through polycarbonate filters (two times
through a 400 nm pore size filter and eight times through a 100 nm pore size
filter) to obtain LUVs. For SPRmeasurements the vesicles were prepared by the
same procedure but extrudedwith a 50-nm pore size (19 times) to obtain smaller
vesicles. The smaller vesicles are preferred in SPR devices to reduce fouling of
microfluidics and because themore strained liposomal curvature imparts greater
surface-volatility, making the liposomes easier to fuse and immobilize.
Secondary structure analysis by
CD spectroscopy
CD measurements were performed to determine the secondary structure of
PrP(106-126) in each lipid solution. CD spectra in the absence and presence
of LUVs composed of POPC/POPG (4:1) (2-mM final lipid concentration)
were carried out with 100 mM PrP(106-126) (giving a peptide lipid/ratio of
1:20) in a quartz cell with an optical path of 0.1 cm at 25C. For these par-
ticular experiments, samples were prepared in buffer containing NaF instead
of NaCl to minimize absorption by the buffer, which may mask peptide
spectral features. Spectra were recorded at wavelengths between 260 and
190 nm with a 0.1-nm step and 20 nm/min speed. Spectra were collected and
averaged over five scans and corrected for background contribution.
Peptide afﬁnity for lipid membranes
followed by SPR
Interaction of PrP(106-126) with lipid bilayers was studied bymeans of SPR.
Liposomes composed of different lipid molar ratios of POPC, POPC/POPG
(4:1), POPC/Chol (2:1), and POPC/GM1 (9:1) were prepared as described in
the preceding section for liposomal preparation. All solutions were freshly
prepared and filtered (0.22 mm) before use in the SPR and the operating
temperature was maintained at 25C throughout the assays. Small liposomal
vesicles (1 mM lipid concentration) were deposited onto the L1 sensor chip
surfaces (2mL/min, 2400 s contact time), consistently reaching a steady-state
plateau during deposition for all lipid mixtures. A short injection ‘‘pulse’’ of
10 mM NaOH (50 mL/min, 36 s) was used to remove loosely bound small
unilamellar vesicles (SUVs), with a final stabilization period of 300 s to
obtain a stable baseline. The immobilization levels were similar, with slight
variations observed for different lipid compositions, but were reproducible
for each composition (POPC ; 5800 response units (RU), POPC/POPG ;
4600 RU, POPC/GM1 ; 5000 RU, and POPC/Chol ; 4800 RU). Liposo-
mal depositions resulting in surface changes of ,6000 RU are more char-
acteristic of supported bilayer structures than intact liposomes, which are
typically .10,000 RU (34,35).
Peptide solutions of PrP(106-126) at different concentrations (0–50 mM)
were then injected over the lipid surfaces. Sensorgrams were compared at
different flow rates to examine mass transfer limitations; however, no mass
transfer effects were found fromflow rates of 5–20mL/min, and the higher flow
rate was used for kinetic analysis. After injection (20 mL/min, 180 s), disso-
ciation was followed for 600 s per injection cycle and the sensor chip surface
was regenerated using cycles of 20 mM CHAPS (5 mL/min, 60 s), 10 mM
NaOH in 20%MeOH (50mL/min, 36 s), and 10mMNaOH (50mL/min, 36 s),
with a final stabilization period of 600 s before subsequent liposomal capture.
The affinity of PrP(106-126) for the lipid bilayer membrane was deter-
mined from analysis and curve-fitting of a series of response curves collected
with different peptide concentrations. When appropriate, association and
dissociation rate constants were globally fitted using BIAevaluation version
4.1. Langmuir and two-state models were used to fit and compare data. In
Langmuir kinetics the interaction follows a simple bimolecular association
between peptide (P) and lipid (L):
P1 L%
kd
ka
PL;
where ka is the association rate constant, and kd is the dissociation rate con-
stant. The corresponding differential rate equation for this reaction model is:
dR=dt ¼ kaCAðRmax  RÞ  kdR;
where R is the response (in RU) that corresponds to the concentration of the
molecular complex formed, CA is the peptide concentration, and Rmax is the
binding capacity of the surface (36).
The two-state model is a modified version of the bimolecular model and
describes a two-phase reaction as follows:
P1 L%
ka1
kd1
PL%
ka2
kd2
PL

:
In this model the first step is the initial peptide interaction with the membrane
and is described by ka1 and kd1. Peptide binding is followed by reorientation
and/or insertion of the peptide into the hydrophobic core (step 2, described by
ka2 and kd2) forming the final state (PL*) of the complex (37,38). The model
assumes that dissociation of PL* must first transition through PL before the
individual species P 1 L can then separate. The corresponding differential
rate equations for this reaction model are represented by
dR1=dt ¼ ka1CAðRmax  R1  R2Þ  kd1R1  ka2R11 kd2R2
and
dR2=dt ¼ ka2R1  kd2R2:
R11R2 is the total observed response. The overall affinity constant, K, is
obtained by fitted parameters as follows:
K ¼ ðka1=kd1Þ=ð11 ka2=kd2Þ:
For cases in which the sensorgrams could not be fit to standard kinetic models
in the association phases (see Fig. 4, A and B) and extended injection times at
lower flow rates did not achieve rates of PrP(106-126)-membrane formation
equal to the rates at which the complex dissociates (allowing equilibrium
constants to be inferred by steady-state approximations), the RU were
converted to pg/mm2 (assuming 1 RU ¼ 1 pg/mm2) at the assay maximum
points (t ¼ 180s) (39). This approach allows the relative affinity to be
assessed and compared based on the amount of PrP(106-126) bound to the
surfaces. The kinetics was measured on these sensorgrams by fitting the
dissociation phases separately from t ¼ 200–700 s.
Membrane effects induced by the presence
of PrP(106-126)
The ability of PrP(106-126) to form pores was tested for different lipidmixtures
with 100 mM final lipid concentration using a methodology based on NBD
fluorescence quenching by Co21 ions (see Henriques and Castanho (40) and
references therein). To follow the permeability of the lipid membrane to Co21
ions, vesicles doped with 1% of N-NBD-PE were prepared with or without 20
mM Co21 inside and outside (positive control). For the positive control, lipid
was hydrated with buffer containing 20 mMCo21, allowing the quencher to be
accessible to NBD in both the outer and in the inner layer. This control was
compared with samples in which Co21 was added after vesicle preparation; in
this case Co21 is accessible only to the outer layer. In the case of pore for-
mation, after peptide addition, Co21 will become accessible to the NBD fluo-
rophores in the inner layer. Different PrP(106-126) and control concentrations
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(0–50mM)were left to incubate for 30min and Co21was added to the samples.
NBD fluorescence emission spectra were followed with lexcitation ¼ 460 nm
before and after PrP(106-126) addition. Data were corrected for the inner filter
effect (41). For this particular assay,MLVswere used instead of LUVs. The use
of MLVs enables a gradual effect to occur in cases of translocation after pore
formation, and therefore allows more reliable reading of the spectroscopic
signals. Several lipid mixtures were used: POPC/POPG (1:0, 19:1, 9:1, 4:1, and
1:1), POPC/Chol (2:1), and POPC/POPG/Chol (47:20:33).
Dipolar potential in the presence of PrP(106-126)
and the pH gradient effect
Membrane dipolar potential is dependent on the orientation of dipoles in the
membrane/water interface. Variation in themembrane dipole potential can be
used to report membrane binding and insertion of molecules by recording fluo-
rescence excitation spectra of di-8-ANEPPS-labeled vesicles, which are par-
ticularly sensitive to dipolar potential variations (42). In this part of the study, 25
mM PrP(106-126) was added to LUVs with 200 mM lipid and 4 mM dye (di-8-
ANEPPS is not fluorescent in aqueous medium). To detect spectral variations in
di-8-ANEPPS excitation, the spectrum (lemission¼ 570 nm) in the absence of the
peptidewas subtracted from the spectrum in the presence of 25mMPrP(106-126)
(both spectra were normalized to total integrated area). This differential spectrum
enables detection of peptide-induced changes in the membrane dipolar potential
(42,43). Fresh solutions and aged peptides (48 h, 37C) were compared in these
experiments. Several lipid compositions were used: POPC/POPG (1:0, 4:1, 7:3,
3:2, 1:1 and 0:1) to evaluate the charge effect; POPC/POPS (4:1) to test any
particular effects with serine; POPC/Chol (1:0, 41:9, and 2:1) to evaluate the
effects of the presence of cholesterol; and POPC/GM1 (1:0, 19:1, 9:1, 4:1, and
1:1) and a mixture of POPC/POPG/Chol/GM1 (37:20:33:10) to test whether a
more complex lipid mixture would improve the interaction with membranes.
Liposomeswith a pH gradient (pH 5.0 inside and pH7.4 outside liposomes) were
prepared to mimic the environment at the endosome/cytoplasm interface. POPC/
POPG (1:1) vesicles were tested. Controls with pH 7.4/pH 5 (in/out), pH 7.4 (in/
out), and pH 5 (in/out) were performed.
RESULTS
Previous works have attributed several toxic properties to the
Prp(106-126) fragment (9,11,24). Our aim was to elucidate the
possible involvement of cellular membranes in the toxicity of
PrP(106-126). LUV model membranes were used in this study
becauseLUVshave a very large curvature at themolecular scale
and can be considered planar for these purposes, and therefore
LUVs are good model membranes to evaluate peptide-mem-
brane interactions (32). Different lipidic mixtures were used to
mimic different membrane properties under three different
buffer conditions: 1), pH 7.4, 150 mM NaCl to evaluate the
membrane-binding properties of PrP(106-126) (analogous to
physiological conditions); 2), pH 5, 150 mM NaCl to evaluate
the possible interaction of PrP(106-126)with endosomeswhere
some toxic PrP species have been localized and possible PrPSc
propagation has been suggested (8); and 3), pH5with low ionic
strength (10 mMNaCl) to evaluate the possible contribution of
electrostatic interactions to membrane affinity.
PrP(106-126) aggregates in aqueous solution
and forms amyloid ﬁbrils
Previous studies have shown that PrP(106-126) tends to ag-
gregate and to form b-structures in a similar manner to the
scrapie PrP isoform (9,44). To verify that the same process
would occur under the conditions of this study, the formation
of b-sheet aggregates was tested by the fluorescence of ThT
and the absorbance of CR. These two dyes are widely used to
detect the formation of amyloid structures (30).
In the absence of b-sheet aggregates, the ThT dye has an
excitation and fluorescence emission maxima at 350 and 438
nm, respectively. In the presence of amyloid fibrils the ThT
spectra shift to 450 nm and 482 nm, respectively (26). During
titration of ThT with PrP(106-126) a slight increase in
the fluorescence intensity at 482 nm, characteristic of ThT
interacting with b-sheet structures, was observed (data not
shown). Although this effect was not strong, it was not un-
expected, since even some b-sheet-rich proteins are report-
edly unable to induce the characteristic ThT fluorescence
(45).
CR absorbance was used to determine whether this peptide
adopts a significant b-sheet conformation. In the case of
amyloid fibril formation, a red shift in the CR absorbance
spectrum at physiological pH is expected (27,28). At pH 7.4,
150 mM NaCl the CR maximum appears at 489 nm. When
CR was titrated with PrP(106-126), a gradual red shift in
absorbance spectra was observed (Fig. 1 A) as a result of an
increase in the component at 535 nm (see differential spectra
inset in Fig. 1 A). At pH 5, 150 mMNaCl, the CR absorbance
spectrum peaks at 502 nm, which is blue-shifted in the
presence of PrP(106-126) (Fig. 1 B). An increase at 496 nm
was detected in the differential spectra (see inset in Fig. 1 B).
At pH 5 the histidine residue is protonated, which increases
the electrostatic effects and the affinity of CR for the peptide,
in agreement with observations for other amyloid peptides
(46). Binding of CR to the peptide leads to a dramatic change
on the spectral shift even in the first peptide addition (2 mM).
Since the spectral shifts stabilize at 1:1 stoichiometry (47),
peptide-peptide interactions at excess peptide (i.e., greater
than 5mM) do not further shift the spectrum because all of the
CR is already bound. However, conformational alterations of
the peptide still occur and lead to alterations in the confor-
mational dynamics of CR, resulting in changes in intensity
even after spectral shifts have reached a maximum (see
Fig. 1 B).
Though the direct comparison of the effects on CR ab-
sorbance at pH 5 and pH 7.4 is not straightforward because
CR absorbance properties change with pH (15,47), we con-
clude that at pH 7.4 and pH 5, PrP(106-126) is able to interact
with CR as an indicator of b-sheet conformation (46).
As a further test, the possibility of peptide aggregation was
also followed by means of ANS fluorescence. The ANS dye
is sensitive to the polarity of its microenvironment and is
frequently used to identify the presence of hydrophobic
‘‘pockets’’ in proteins and peptides (29–31). In the presence
of hydrophobic ‘‘pockets’’, ANS fluorescence emission in-
tensity increases and concomitantly undergoes a blue shift.
Titration of ANS with PrP(106-126) at pH 7.4 (150 mM
NaCl) causes an increase in the fluorescence intensity and a
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significant blue shift (59 nm) of the maxima of ANS emission
(Fig. 2), which is indicative of the presence of aggregates in
solution. This same shift was also detected at pH 5 and for both
for low and physiological ionic strengths (data not shown).
CD spectroscopic analysis of PrP(106-126)
secondary structure
The results of the experiments with ThT and CR dyes, and
previous publications (14) on PrP(106-126) secondary
structure, suggest the presence of b-sheet secondary structure
in solution. CD was therefore used to study the secondary
structure of the peptide upon interaction with the model
membranes. Fig. 3 shows the CD spectra of 100 mM
PrP(106-126) in the presence and absence of POPC/POPG
(4:1) LUVs ([Lipid] ¼ 2 mM), with no a-helix signal found
under any conditions (double minima bands at 208 and 222
nm, and a positive band at 192 nm). Under acidic conditions
the CD spectra have a predominantly random coil structure
(as characterized by the well-defined strong negative minima
at ;195 nm). Upon interaction with membranes, there is a
shift to 204 nm and a concomitant decrease in intensity,
without gains in characteristic a-helix components, indicat-
ing that an extended conformation is predominant in the
FIGURE 1 Identification of b-structures in
the PrP(106-126) by CR absorbance. Absor-
bance spectra of 5 mM CR in the presence of
PrP(106-126) 0–50 mM (A) at pH 7.4, 150 mM
NaCl, and (B) at pH 5, 150 mM NaCl. Absor-
bance was normalized to highlight the red shift
at pH 7.4 and the blue shift at pH 5.0 upon
peptide addition. (Inset) Initial CR absorbance
spectrum was subtracted to all the spectra
obtained after peptide addition at pH 7.4 or
pH 5. At pH 7.4 an increase is seen in the CR
absorbance at 535 nm with peptide concentra-
tion, and at pH 5 there is an increase at 496 nm.
This indicates that PrP(106-126) is interacting
with CR, which suggests that PrP(106-126) has
a b-structure. This effect is stronger at pH 7.4
compared to pH 5.
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presence of membranes. Under physiological conditions
there was no alteration in the minima position in the presence
of liposomes. Overall, the results demonstrate that PrP(106-
126) has no discernible helicity and very little secondary
structure in the presence or absence of the POPC/POPG
membranes at different pHs.
PrP(106-126) interaction with
membranes—kinetics and afﬁnity
The interaction and affinity of PrP(106-126) for lipid bilayers
was studied by means of SPRwith lipid membranes adsorbed
onto an L1 sensor chip, which contains a dextran matrix with
substituted lipophilic alkyl chains that give the surface lipo-
philic properties. SPR has proven to be a valuable experi-
mental approach to study the interaction of peptides with
lipid bilayers, which allows the real-time monitoring of
peptide binding to and dissociation from lipid bilayers, and
has the advantage of obviating the need to use labeled pep-
tides or lipids (38). Liposomes are captured on the surface of
the sensor chip and the peptide is passed across the formed
membrane. SPR detects changes in the refractive index at a
maximal depth of 300 nm in the flow cell, providing real-time
measures of association/dissociation of the peptide at the
membrane sensor surface. The surface RU is proportional to
the adsorbed mass on the sensor surface (38).
In this study we examined the association/dissociation of
PrP(106-126) with membranes using different lipid compo-
sitions to gain more insight into the parameters that govern
the membrane affinity and selectivity of the peptide. Model
membranes of POPC were compared with membranes with
more complex lipid compositions, such as POPC/POPG
(4:1), POPC/Chol (2:1), and POPC/GM1 (9:1).
Phospholipids with a phosphatidylcholine (PC) headgroup
are the major component in mammalian cell membranes (48).
POPC vesicles at room temperature are in fluid phase and can
be used to represent the bulk phase in cell membranes.
Negatively charged phospholipids are more abundant in the
inner leaflet of the plasma membrane (48) and have been
implicated in amyloid fibril stimulation in vivo (49). The
potential role of negatively charged lipids in the membrane
binding of PrP(106-126) was therefore evaluated through the
use of membranes composed of POPC/POPG. This binary
mixture maintains fluid phase properties.
Because neuronal cell membranes are enriched with cho-
lesterol, and a specific involvement of cholesterol has been
implicated in PrPC-PrPSc conversion in prion-infected cell
lines from cholesterol-depletion studies (50,51), the possible
interaction of PrP(106-126) with cholesterol was also tested
with vesicles composed of POPC/Chol (2:1), which presents
a homogeneous liquid-ordered phase (52). Therefore, the
effect of membrane rigidity on peptide-membrane interaction
can be studied and compared with membranes on fluid phase.
Finally, GM1 is a ganglioside that is abundantly expressed in
neurons and concentrated in caveolae and lipid raft regions,
and has been shown to bind specifically to the Alzheimer’s
Ab peptide leading to the induction of b-structure (53–55)
and possibly membrane disruption (56). The similarities in
the amyloidogenic properties of the Ab peptide and PrP in
prion disease raises the question as to whether GM1may also
induce b-structure in PrP(106-126), and whether GM1 may
be involved in the membrane affinity of PrP(106-126). This
possibility was explored in this study using vesicles com-
posed of POPC/GM1(9:1). At this lipid ratio, GM1 has been
reported to form rigid microdomains in the PC bilayer
(57,58).
The effect of pH and ionic strength on the interaction of
PrP(106-126) with POPC is shown in Fig. 4 A, and the in-
fluence of lipid composition at low pH and ionic strength is
shown in Fig. 4 B. The sensorgrams indicate that under
FIGURE 2 Aggregation of PrP(106-126) evaluated by
ANS fluorescence properties. The effect of peptide con-
centration in 12.5mMANS fluorescence emission spectrum
(lexcitation ¼ 369 nm, pH 7.4, 150 mM NaCl). Spectra were
normalized to highlight the ANS blue shift upon interaction
with PrP(106-126). (Inset) Dependence of integrated fluo-
rescence intensity of ANS with peptide concentration. A
significant blue shift and a concomitant increase in ANS
fluorescence intensity indicate that this peptide is in an
aggregated form.
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physiological conditions (pH 7.4, 150 mMNaCl) the peptide
does not bind as strongly to POPC membranes, with only
17.3 pg/mm2 PrP(106-126), bound at t¼ 180 s (see Fig. 4 A).
Whereas a slightly better interaction is evident for POPC at
pH 5, 150 mM NaCl (47.1 pg/mm2), a significant increase in
the RU signal is observed at pH 5 and low ionic strength (164
pg/mm2).
A comparison of the POPC membrane binding and POPC/
POPG (4:1) reveals a significant charge effect with an in-
crease in the amount of peptide bound in the presence of the
anionic phospolipid (Fig. 4 B, Table 1). In contrast, the in-
teraction of PrP(106-126) with POPC/Chol (2:1) and POPC/
GM1 (9:1) was weaker than that with POPC under all buffer
conditions tested (Fig. 4 B, Table 1). However, it is note-
worthy that although there was less material bound to the
cholesterol and GM1 membranes, there was also a slower
dissociation from the membrane in the presence of choles-
terol and GM1 (Table 1).
A kinetic analysis of concentrations of PrP(106-126) up to
25 mM with POPC and POPC/POPG(4:1) at pH 5, 10 mM
NaCl, conditions (Fig. 5) shows that PrP(106-126) has a
higher affinity for the POPC/POPG membranes at pH 5 (low
ionic strength). The PrP(106-126) interaction with these
membranes follows a two-state binding model, which as-
sumes that a change occurs in the structure and/or orientation
FIGURE 3 CD spectra of 100 mM PrP(106-126) in the presence and
absence of POPC/POPG (4:1) LUVs ([Lipid] ¼ 2 mM). Three conditions
were tested: 10 mM HEPES buffer, pH 7.4, 150 mM NaF; 20 mM acetate
buffer, pH 5, 150 mM NaF; and 20 mM acetate buffer, pH 5, 10 mM NaF.
No a-helix (double minima bands at 208 and 222 nm and a positive band at
192 nm) is observed for PrP(106-126) under any conditions. At pH 5 (but
not pH 7.4), the CD spectra have a strong negative band at 198 nm (random
coil structure), with a shift upon interaction with membranes to 204 nm.
Both minima in the presence and absence of membranes remain at the same
wavelength for pH 7.4 conditions (204 nm).
FIGURE 4 Influence of lipid and buffer composition on peptide affinity
for membranes. (A) pH and ionic strength effect on PrP(106-126) (25 mM)
interaction with POPC membranes immobilized on the surface of an L1
chip. HEPES buffer pH 7.4, 150 mM NaCl; acetate buffer pH 5, 150 mM
NaCl; and acetate buffer pH 5, 10 mMNaCl were used. The peptide does not
show a significant affinity for membranes under physiological conditions. At
acidic pH a marked increase in the membrane-bound peptide is observed,
which is significantly enhanced at low ionic strength. (B) The affinity of 25
mM PrP(106-126) for membrane surfaces on L1 chips is shown for different
lipidic compositions at pH 5, 10 mM NaCl. Compositions are: POPC,
POPC/POPG (4:1), POPC/Chol (2:1), and POPC/GM1 (9:1). PrP(106-126)
has a lower binding to POPC/Chol and POPC/GM1 relative to POPC and the
highest affinity for the anionic membrane.
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of the peptide after initial binding to the membrane. The two-
state binding model resulted in a significant improvement in
fit quality compared to the 1:1 Langmuir model (the two-state
kinetic and affinity constants are presented in Table 2). In this
model the values ka1/kd1 characterize the first step or ‘‘en-
counter complex’’, whereas ka2/kd2 describe peptide re-
orientation and/or insertion of the peptide into the
hydrophobic core. The importance of electrostatic forces on
PrP(106-126) membrane binding is evidenced by larger as-
sociation rates (ka1¼ 5.043 102 1/Ms, ka2¼ 5.33 103 1/s
for POPC, and ka1¼ 21.43 102 1/Ms, ka2¼ 13.73 103 1/s
for POPC/POPG 4:1) and larger overall affinity constants
(K ¼ 1.26 3 105 1/M, and 4.39 3 105 1/M for POPC and
POPC/POPG (4:1), respectively) in the presence of neg-
atively charged phospholipids.
PrP(106-126) does not form ionic channels under
physiological conditions
One possible mechanism by which PrP(106-126) exerts toxic
effects is via channel formation across cell membranes. To
determine whether pore formation occurs, we took advantage
of the ability of Co21 to quench NBD fluorophores (for
further details see the Materials and Methods section). SPR
results demonstrated that PrP(106-126) binds preferentially
to vesicles with negatively charged phospholipids. The re-
sults in Fig. 6 show that PrP(106-126) was not able to make
vesicles permeable to Co21 ions, regardless of the molar ratio
of POPG tested at physiological conditions. At acidic pH,
significant quenching was only apparent at low ionic strength
(10 mM NaCl) and a high POPG molar ratio (1:1; Fig. 6).
These results demonstrate that Co21 permeability can only be
achieved when electrostatic interactions are dominant be-
tween PrP(106-126) and negatively charged vesicles. Serine-
containing glycerophospholipids are the most common
negatively charged phospholipids present in mammalian
cells. To evaluate whether there is any particular effect with
serine, POPC/POPS was also tested and no difference was
observed in the capacity to induce channel formation (results
not shown). The presence of cholesterol and GM1 was also
tested by the use of liposomes composed of POPC/Chol (2:1)
and POPC/GM1 (9:1), but no leakage was observed in these
liposomes or in the more-complex lipid mixtures of POPC/
POPG/Chol (47:20:33) in any of the buffer conditions tested.
Effect of PrP(106-126) on membrane potential
and the pH gradient
Peptide insertion into lipid bilayers will perturb the mem-
brane dipolar potential, which can be monitored by means of
a spectral shift in the excitation spectra of di-8-ANEPPS (43).
This dye is located in the lipid headgroup region, where it is
sensitive to the local electric field (42). To screen the inter-
action of PrP(106-126) with membranes, a fresh or aged
solution of 25 mM PrP(106-126) was added to liposomes
with different lipid compositions: POPC/POPG (1:0, 4:1,
7:3, 3:2, 1:1, and 0:1), POPC/POPS (4:1), POPC/Chol (1:0,
41:9 and 2:1), POPC/GM1 (1:0, 19:1, 9:1, 4:1, and 1:1), and
a mixture of POPC/POPG/Chol/GM1 (37:20:33:10). A no-
ticeable spectral shift in di-8-ANEPPS was only observed at
TABLE 1 The amount of PrP(106-126) bound to and
dissociation rate (kd) from POPC, POPC/POPG (4:1), POPC/Chol
(2:1), and POPC/GM1 (9:1) membranes assayed in acetate
buffer, pH 5 (10 mM NaCl)
Lipid type Peptide bound (pg/mm2) kd (310
3 1/s)
POPC 164 1.1
POPC/POPG (4:1) 225 0.77
POPC/Chol (2:1) 72.7 0.46
POPC/GM1 (9:1) 48.5 0.67
Amount of peptide bound to membranes was calculated after 25 mM
injection at the assay maxima points (t ¼ 180 s) (assuming 1 RU ¼ 1 pg/
mm2; see Fig. 4 B). Dissociation constants were obtained after dissociation
curve-fitting using BIAevaluation version 4.1.
FIGURE 5 Global two-state kinetic analysis of SPR data PrP(106-126) in
the presence of (A) POPC or (B) POPC/POPG (4:1) membranes captured on
L1 chip surfaces. Peptide samples (5, 10, 15, 20, and 25 mM) were prepared
in acetate buffer (pH 5, 10 mM NaCl) and injected at 20 mL/min flow rate.
Sensorgrams were corrected for bulk shift effect (shaded lines) and a two-
step binding model was fitted to data with BIAevaluation version 4.1 (solid
lines). Kinetic and affinity constants are presented in Table 2.
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pH 5 (10 mM NaCl) in lipid vesicles composed of POPC/
POPG (1:1) (Fig. 7).
Because a pH gradient can promote the translocation of
some peptides across a membrane (59), we also investigated
whether a pH gradient across the endosomes/cytoplasm can
promote PrP(106-126) interaction with membranes and
subsequently induce membrane translocation. With a con-
stant ionic strength (150 mM NaCl), a pH gradient across
membranes was created in POPC/POPG (1:1). Liposomes
with pH 5/pH 7.4 (in/out) were compared with pH 7.4/pH 5
(in/out), pH 7.4 (in/out), and pH 5 (in/out) 150 mMNaCl. No
significant differences were detected between the samples
with a pH gradient and the controls (see Fig. 7).
DISCUSSION
Prion disease is initiated by conversion of physiological
PrPC, a protein abundantly expressed in mammalian brain,
into a pathological isoform, PrPSc, which accumulates within
the brain as highly toxic insoluble aggregates (1). The neu-
rodegeneration rate verified in prion disease cannot be ex-
plained solely by PrPSc formation and deposition (6). Some
other PrP toxic species have been identified inside the cells,
which seem to have an important role in disease propagation
and transmission after infection by PrPSc (6). A neurotoxic
PrP fragment, PrP(106-126), that has physicochemical
properties similar to PrPSc and is present in all abnormal toxic
FIGURE 6 Cross-bilayer channel formation induced by PrP(106-126) in
100 mM POPC/POPG (1:1) vesicles followed by NBD quenching by Co21.
The ratio of NBD fluorescence emission (lexcitation¼ 460 nm) in the absence
of quencher (I0) and the presence of 20 mM Co
21 (I), for the vesicles with
Co21 accessible to both layers (open columns) and for the vesicles where
Co21 is only accessible to the outer layer (solid columns), is presented for
different peptide concentrations. These experiments were carried at pH 5 (A)
150 mM NaCl or (B) 10 mM NaCl. A comparison of the results (solid
columns) with the positive control (open columns) demonstrates that pores
are not formed, even at a high peptide/lipid ratio (1:2, for 50 mM PrP(106-
126)), at 150 mM NaCl. At 10 mM NaCl there is increased leakage of Co21
with increasing peptide concentration.
TABLE 2 Association (ka1 and ka2), dissociation (kd1 and kd2), and afﬁnity constant (K) of PrP(106-126) binding to POPC and
POPC/POPG (4:1) assayed in acetate buffer, pH 5 (10 mM NaCl)
Lipid type ka1 (310
2 1/Ms) kd1 (310
2 1/s) ka2 (310
3 1/s) kd2 (310
3 1/s) K (3105 M1) x2
POPC 5.05 1.35 5.30 1.56 1.26 5.14
POPC/POPG (4:1) 21.4 5.69 13.7 1.17 4.39 13.9
Binding constants were obtained after fitting the SPR data from Fig. 5 to a two-state binding model with BIAevaluation version 4.1. Experimental conditions
are described in the legend of Fig. 5.
FIGURE 7 PrP(106-126) effect in the dipolar potential of POPC/POPG
(1:1) vesicles followed by fluorescence difference spectra of Di-8-ANEPPS-
labeled vesicles. The excitation spectrum obtained in the absence of peptide
was subtracted to the spectrum obtained in the presence of 25 mM PrP(106-
126); both spectra were normalized to the integrated areas to reflect only the
spectral shift. The difference spectrum obtained in acetate buffer, pH 5 (10
mM NaCl), has a more pronounced shift than the other four difference
spectra obtained with 150 mMNaCl (pH 7.4, pH 5) or with a pH gradient pH
7.4/pH 5 (in/out) and pH 5/pH 7.4 (in/out). PrP(106-126)’s effect on the
dipolar potential is therefore independent of pH or pH gradient, but depends
on ionic strength.
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species within the patient brain has been used as a model of
PrPSc to study the possible mechanism of disease propagation
and transmission (9–12,14,44). However, PrP(106-126) tox-
icity remains controversial in the literature. Nonselective pore
formation leading to ionic gradient destabilization has been
proposed as a mechanism by which PrP(106-126) exerts its
neurotoxic effects (19); however, channel formation was not
reproduced in some reports (21) and the neurotoxicity of this
peptide was verified only in the presence of PrPC (17,18).
The aim of this work was to determine whether PrP(106-
126) interacts with model membranes, and whether this in-
teraction correlates with the biological toxic effects of
PrP(106-126). PrP(106-126) was characterized in the ab-
sence/presence of liposomes under three different buffer
conditions. Whereas PrP(106-126) formed aggregates in the
buffer solutions used (Fig. 2), no significant secondary
structure was apparent in the presence of liposomes (Fig. 5).
The interaction of PrP(106-126) with lipid membranes was
evaluated by SPR and correlated with fluorescence method-
ologies that report on variations in the dipolar potential at the
membrane. Under physiological conditions of pH 7.4 and
150 mM NaCl, PrP(106-126) interacted relatively weakly
with all lipid mixtures used. A lower affinity for membranes
at physiological buffer conditions was confirmed by mem-
brane dipolar potential studies and leakage measurements.
Moreover, neither PrP(106-126) insertion nor membrane
leakage was observed under any of these conditions.
At pH 5, the histidine residue at position 6 in the PrP(106-
126) sequence is ionized and the formal net charge of the
peptide increases from 12 (contributed from the two lysine
residues) to 13 (6). With pH 5, 150 mM NaCl, a slight in-
crease in membrane affinity was detected by SPR on POPC
membranes (Fig. 4 A). This affinity was greatly increased
with low ionic strength (10 mM NaCl) (Fig. 4 A, topmost
sensorgram) and in the presence of POPG (a negatively
charged phospholipid) (Fig. 4 B). Under these conditions,
electrostatic interactions between the positively charged
peptide and negatively charged membrane are enhanced,
which increases the overall peptide-membrane affinity (see
Table 2); however, no insertion or pore formation was de-
tected as verified by monitoring membrane dipolar variation
and by leakage experiments.
It has been suggested that amyloid formation is stimulated
in the presence of a hydrophobic environment at acidic pH
(60). Our results show no significant secondary structure
in the presence or absence of lipid under different buffer
conditions (see Fig. 5). SPR shows that the interaction of
PrP(106-126) with membranes at pH 5 10 mM NaCl can be
described by a two-state model. The two states may be
identified as: step 1), peptide interaction with the membrane
interface (primarily governed by electrostatic interactions
between the peptide and the membrane); and step 2), the
peptide undergoes a secondary structure modification at the
bilayer surface/or lipidic rearrangements occur in the mem-
brane, resulting in a complex that cannot dissociate from the
surface without first transitioning back through the kinetic
pathway. This second step involves underlying thermody-
namic events, including a transition of the peptide into the
plane of binding, which depends on the hydrophobic/
hydrophilic balance of the molecules groups and forces
involved (61) and can be dependent on the interfacial hy-
drophobicity of the peptide (62). For PrP(106-126), a White-
Wimley hydrophobicity prediction (see Fig. 8) does not favor
interfacial partitioning irrespective of the peptide charge
state, and so an increase in partitioning at low ionic strength
results from the increase in peptide concentration close to
membrane environment and is dependent on the electrostatic
interactions of the membrane and peptide. Furthermore, be-
cause no insertion or dipole changes were detected with the
membrane under any of the fluorescent experiments to sup-
port an insertion hypothesis, we conclude that the second
step in the two-state interaction can only be subtle peptide-
membrane changes local to the membrane surface.
The SPR experiments also indicated that PrP(106-126)
does not bind specifically to ganglioside GM1 or cholesterol.
GM1 has a tendency to form microdomains in PC mem-
branes (57,58) and is known to bind the Alzheimer’s Ab
peptide, leading to the induction of b-structure (53–55) and
possibly membrane disruption (56). However, the SPR and
fluorescence data indicate that clustering of GM1 in more
organized patterns may actually hinder the interaction of
PrP(106-126) with POPC due to steric constraints of the
sugar headgroups leading to an apparent lower affinity for
POPC/GM1 than for POPC at acidic pH (Fig. 3 B). However,
the kd values suggest that although lower amounts of peptide
bound to the GM1 surface, once the peptide interacts with the
surface it remains bound for a longer period of time.
Some observers have suggested that cholesterol may play a
role in decreasing PrPC-PrPSc conversion (50,51); therefore,
cholesterol was specifically included in this study. POPC/
Chol (2:1) vesicles have a homogeneous liquid-ordered
phase. However, the combined evidence of reduced affinity
FIGURE 8 Theoretical analysis of PrP(106-126) partition into interfacial
membrane region-based free-energy change DGwif from water transfer to the
lipid membrane interface (see White and Wimley (62)). Residues with
values DGwif , 0 have a tendency to be transferred from the water phase to
the membrane.
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observed by SPR, lack of fluorescence evidence for mem-
brane changes, and lack of peptide insertion or leakages leads
us to conclude that PrP(106-126) does not bind specifically to
cholesterol in the plasma membrane and does not have a
preference for the liquid-ordered phase.
Membrane insertion and channel formation, as determined
from Co21 leakage and variation of the membrane dipolar
potential, were detected only with model membranes com-
posed of POPC/POPG (1:1) at pH 5, 10 mM NaCl. Under
these extreme conditions the membrane has a strong negative
charge and the low ionic strength is not sufficient to prevent a
strong electrostatic attraction to the positively charged pep-
tide. The possible importance of endosomes in PrP propa-
gation was evaluated by mimicking the pH gradient in the
cytoplasm/endosome environment. The pH gradient (pH 7.4/5
(in/out) or pH 5/7.4 (in/out)) could eventually be a driving
force for peptide insertion in the membrane, as observed for
other peptides (59). However, both pH gradient systems
failed to show any evidence that PrP(106-126) inserts into the
membrane (see Fig. 7).
Altogether, these peptide-membrane studies show that PrP
(106-126) does not have a strong affinity for lipid membranes
under conditions similar to the cytoplasmic environment.
Under conditions that mimic the endosomal environment,
PrP(106-126) also has a weak interaction with membranes,
and in these conditions no insertion or pore formation were
detected.
These observations indicate that the toxic effects of
PrP(106-126) cannot be explained by cell membrane leak-
age. Alternatively, it can be hypothesized that the PrP(106-
126) toxic effects occur inside the cell. Such suggestions
imply PrP(106-126) cellular internalization, which is a phe-
nomenon that has been demonstrated for several peptides,
such as the cell-penetrating peptides (CPPs) family (63). The
uptake of CPPs can follow two routes: one is physically
mediated and the other is dependent on the endosomal
pathway. Both routes require peptide-membrane interactions
as the first step (64). With the lack of affinity of PrP(106-126)
for lipid membranes, both routes for cell entry can be dis-
counted, unless the cellular internalization of PrP(106-126)
occurs via a mechanism mediated by the presence of physi-
ological PrP (e.g., mediated by caveolae or rafts where PrP is
colocalized on the cell surface). The N-terminal domain of
PrP with a noncleaved signal sequence has been included in
the CPP family because of its ability to translocate across cell
membranes (65). This sequence may be responsible for the
internalization of sizeable cargo into cells (65). It has been
suggested that this N-terminal domain is implicated in PrP
trafficking as well as in prion infectivity (65). A possible
internalization of PrP(106-126) in cells mediated by this
N-terminal domain of PrP could explain the possible toxic
effects inside cells after internalization.
In the work presented here, we tested whether PrP(106-
126) has affinity for the membrane in an endosomal-like
environment. An increased propensity to interact with lipid
bilayers (see Fig. 3 A) was evident; however, this does not
represent a significant membrane insertion (see Fig. 7) or an
improved tendency to form a transmembrane pore. This is in
agreement with previous findings that the fibrillogenic
properties alone are not sufficient for neurotoxicity, as veri-
fied by other PrP fragments that were able to assemble into
filaments but lacked toxic effects (9). Moreover, even with a
pH gradient across the membrane, similar to the endosomal/
cytoplasmic interface, no insertion in the membrane was
observed. Therefore, in the case of the PrP(106-126) frag-
ment endosomal internalization, the toxic effect cannot be
explained by acidic pH. Altogether, our data lead us to
conclude that pore formation or any direct effect on mem-
brane properties does not occur and hence is not involved in
PrP(106-126) toxicity.
Our results corroborate previous reports in which pore
formation was not detected in the presence of PrP(106-126)
(21). Studies performed with the complete PrP molecule have
also proposed membrane leakage as a possible mechanism
for toxicity (66,67). In these studies, membrane leakage was
performed with SUVs composed of POPG and in the absence
of salt (66,67). Liposomes with such characteristics are un-
stable not only because of the high membrane curvature (32)
but also because of charge repulsion in the absence of counter
ions. Moreover, leakage of zwitterionic membranes com-
posed of POPC or DPPC/Chol/sphingomylin was not sig-
nificant (67). When these observations are combined with the
results of the study presented here, it is possible to conclude
that PrP(106-126) disturbs the lipidic bilayers only in ex-
treme conditions. This in turn adds weight to the hypothesis
that PrPC may be necessary to mediate PrP(106-126) toxicity
(12). One possible mechanism is that the peptide kills neu-
rons by modification/inhibition of a physiological function of
PrPC. In such a scenario, PrP(106-126) toxicity would be
related to a loss of PrP function rather than a gain of toxic
properties in the presence of PrP(106-126) (12).
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